about
Glucagon and heart in type 2 diabetes: new perspectivesThe Possible Role of Flavonoids in the Prevention of Diabetic ComplicationsExtracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?Metabolic syndrome, serum uric acid and renal risk in patients with T2D.[Gender differences of at risk patients with overt heart failure in the real world of general practice. Data from the GIPSI (Gestione Integrata Progetto Scompenso in Italia) registry].Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiativeA Therapeutic Challenge: Liddle's Syndrome Managed with Amiloride during PregnancyAge- and glycemia-related miR-126-3p levels in plasma and endothelial cells.The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report.Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey.Short-term high glucose exposure impairs insulin signaling in endothelial cells.Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells.Is there a relationship between factor V Leiden and type 2 diabetes?Type 1 diabetes and cardiovascular diseaseLiraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.Cardiovascular guidelines: separate career may help attenuate controversy.Evidences of +896 A/G TLR4 polymorphism as an indicative of prevalence of complications in T2DM patients.Blood glucose pattern management in diabetes: creating order from disorder.Nutritional imbalances linking cellular senescence and type 2 diabetes mellitus.Self-care, quality of life and clinical outcomes of type 2 diabetes patients: an observational cross-sectional study.Focus on migrants with type 2 diabetes mellitus in European Countries.A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.Atherogenicity of postprandial hyperglycemia and lipotoxicity.Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications.Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes.Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients.Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes.Improved Glucose Profile in Patients With Type 2 Diabetes With a New, High-Protein, Diabetes-Specific Tube Feed During 4 Hours of Continuous Feeding.Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes.A rare genetic variant of BPIFB4 predisposes to high blood pressure via impairment of nitric oxide signaling.Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress.Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy.Wolfram syndrome 2: a novel CISD2 mutation identified in Italian siblings.The pivotal role of high glucose-induced overexpression of PKCβ in the appearance of glucagon-like peptide-1 resistance in endothelial cells.
P50
Q26738580-E78790B5-57A8-4988-83B3-134EDBC4DBD3Q26746903-5081A2F5-66CF-4F35-A26F-74AC17951DD2Q28079163-1619D0FE-61E3-4A50-B31C-D6EAA751C1C6Q33579624-7015D6A4-6221-4155-896A-D575D8532003Q33605121-1CF36208-D953-48C5-90B5-86FF39777463Q33789640-1E946AFA-A99C-42F7-81DF-E0764EB97924Q34152668-52FADD80-0532-4804-BF27-0E7EA9A37016Q34461150-69C7873A-A28B-4D1F-8ABA-002B65AF54DDQ34558538-3EF479B8-11C8-4320-ACCE-9916614D51C8Q35958467-01BCD555-64F0-4BB9-9AD4-FA887844CD18Q35987010-D3BB48F3-4ACF-4AAB-91C0-EFC637A563D4Q36855706-793DDF40-33AD-4FA4-ABCB-5FB59105CFACQ37255622-94676016-FDA0-4BE9-B370-303B28941FA6Q37277055-762A4E16-C79A-4ED5-941B-527122DC4BB9Q37470522-A70653F9-FA42-4F1B-A1CA-EF796EE75ABFQ37680440-CD0109C4-BCA1-4299-BD30-756F7B2BAA3DQ37717813-F0F4BA03-C742-48A8-B517-069E090FD8D5Q38172312-AB29D2C4-686C-4BAB-A492-AEA139C549F3Q38212701-2C6EAA8B-A4BE-4903-8102-821C071CD0B6Q38602676-E52F6675-7CBC-4D23-A097-5780D60D0DBBQ38674822-24203829-6E66-426B-B65C-191BC0C934B3Q38694894-4884FFE8-2BA0-4597-A61B-B4F65698DA87Q38734928-50B012C7-644C-4E6C-8CD5-9A05F6E16720Q38795832-C2C10332-4DDB-42BA-86B9-75952DB9FE3CQ39113201-FF9367F9-5633-44B0-8BFB-A52F578AB391Q39115570-CFD7DA25-DBE8-4918-A886-94F1FBFE9380Q39255188-303D6763-9FCF-4957-82E9-18EA1BFFF85DQ39419837-E0BA02EE-9FB8-459F-95A7-F72E69E09F24Q39536895-C94D0E89-1F6F-4038-8ECB-E3874ADE70FBQ39560495-D7DAD55B-8767-40EC-82C5-CC662CB44F79Q40041605-82A66A81-9BD3-49B9-88FA-7C2676EF54D2Q40232094-A6FD3BA3-85AE-4E63-ABE8-97BF3407858AQ41547889-024A6119-683B-4A17-BAE5-AD2F5D7111B9Q42317083-DB1FF152-EF43-4B1D-835F-C15FA09F0F55Q42555659-E94FA098-5B76-4759-9C96-46FA124EB6A2Q42577978-CFE54DD2-EFD5-4D7E-86FC-2FF4E0D9227FQ43409321-C1F6B966-BB4E-4526-94A9-14BA978781ADQ43447053-A96D62B3-5E89-4AFF-BE53-1FA687627CCFQ45181218-C6EBBA0C-C4CE-4AC8-99C2-9895D2A64A84Q46470578-FEB8D70C-999B-493B-95D2-0D38E8070A3C
P50
description
researcher
@en
wetenschapper
@nl
name
S Genovese
@en
S Genovese
@nl
type
label
S Genovese
@en
S Genovese
@nl
prefLabel
S Genovese
@en
S Genovese
@nl
P106
P31
P496
0000-0002-6085-437X